Results 101 to 110 of about 76,283 (157)
Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases. [PDF]
Drug Des Devel TherDai R, Lou N, Zheng X, Han X.
europepmc +1 more source
Selective Janus kinase inhibitors exhibit different effects in murine immune aplastic anemia. [PDF]
HemasphereDurrani J +10 more
europepmc +1 more source
Treatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series. [PDF]
Case Rep DermatolZhao G, Liu Y, Ni J, Song Z.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
Cochrane Database of Systematic Reviews, 2015Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J, Martí-Carvajal +2 more
openaire +4 more sources
Seminars in Oncology, 2009
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire +2 more sources
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire +2 more sources
Malignancy and Janus Kinase Inhibition
Rheumatic Disease Clinics of North America, 2017The use of biologics such as anti-tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung cancer, and nonmelanoma skin cancers (NMSCs) is greater in patients with RA compared with the general population.
Padmapriya, Sivaraman, Stanley B, Cohen
openaire +2 more sources
Negative Regulation of Janus Kinases
Cell Biochemistry and Biophysics, 2001The precise regulation of both the magnitude and the duration of Janus kinase (JAK) catalytic activity is essential for the cytokine orchestration of many biological processes, and the dysregulation of JAK activity has pathological implications.
R J, Duhé, L H, Wang, W L, Farrar
openaire +2 more sources
Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]
Postgraduate Medicine, 2013 Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
Srdan Verstovsek
exaly +3 more sources
Investigational Janus kinase inhibitors
Expert Opinion on Investigational Drugs, 2013Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire +2 more sources